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Abstract
Hepatocellular carcinoma is the fastest growing cause 
of cancer related death globally. Sorafenib, a multi-
targeted kinase inhibitor, is the only drug proven to 
improve outcomes in patients with advanced disease 
offering modest survival benefit. Although comprehensive 
genomic mapping has improved understanding of the 
genetic aberrations in hepatocellular cancer (HCC), this 
knowledge has not yet impacted clinical care. The last 
few years have seen the failure of several first and second 
line phase Ⅲ clinical trials of novel molecularly targeted 
therapies, warranting a change in the way new therapies 
are investigated in HCC. Potential reasons for these 
failures include clinical and molecular heterogeneity, trial 
design and a lack of biomarkers. This review discusses 
the current crisis in HCC drug development and how we 
should learn from recent trial failures to develop a more 
effective personalised treatment paradigm for patients 
with HCC. 
Key words: Hepatocellular carcinoma; Molecular targets; 
Genomics; Sorafenib; Tyrosine kinase inhibitors
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Core tip: This review discusses the current drug therapy 
landscape for advanced hepatocellular carcinoma, in 
particular the reasons for failure of several clinical trials 
of molecularly targeted therapy and future directions of 
research to address these problems.
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INTRODUCTION
Hepatocellular cancer (HCC) is the sixth most prevalent 
cancer worldwide and accounts for over 745000 deaths 
a year[1]. Despite the implementation of screening 
programs for high-risk individuals, the majority of patients 
present with incurable disease. Median overall survival for 
advanced disease remains poor at less than 12 mo and 
there is an urgent need for more effective treatments[2]. 
Global epidemiological patterns vary depending on the 
prevalence of risk factor. Incidence rates are highest in 
East Asia in areas where hepatitis B and C are endemic[3]. 
However, improved management of early viral hepatitis 
in Japan has seen a reduction in new HCC cases[4]. By 
contrast the upward trends of HCV, obesity and metabolic 
syndrome in North America and Europe contribute to 
HCC being the fastest growing cause of cancer related 
mortality in these regions[5]. Resection, radiofrequency or 
microwave ablation, and liver transplantation comprise 
the mainstay of treatment for early disease offering the 
only chance of cure, but only one third of patients present 
with disease suitable for these treatments[6]. Loco-regional 
therapy with trans-arterial chemoembolization (TACE) 
can lead to sustained disease control for intermediate 
stage HCC[7,8]. Sorafenib, a multi-targeted tyrosine 
kinase inhibitor (TKI), remains the only systemic therapy 
that is effective in advanced disease offering marginal 
survival benefit without significant improvement in cancer 
related symptoms or quality of life[2]. After many years 
of disappointing results with chemotherapy, sorafenib 
was thought to herald a new era in HCC treatment 
with great optimism for molecularly targeted therapies. 
Disappointingly, several negative first and second line 
phase Ⅲ clinical trials ensued. However, the combination 
of recent extensive genomic studies and biomarker based 
clinical trials, provide hope for the development of a more 
personalised treatment paradigm. This review discusses 
the current concepts and management of advanced HCC 
with a particular focus on the failure of molecular targeted 
therapy beyond sorafenib and outlines how this should be 
addressed. 
Current therapy for advanced disease
Despite only marginal benefits with chemotherapy 
reported in single arm studies, lack of alternative treat-
ments meant its use was routine prior to the advent of 
sorafenib. Challenges with toxicities (especially in patients 
with underlying liver disease) led to chemotherapy being 
reserved for patients with good performance status 
and preserved hepatic function. Single agents such as 
doxorubicin, cisplatin and fluorouracil offer response rates 
of 10%[9-11]. This increases to 20% with combination 
regimens, none of which impact survival[9,12]. The recently 
reported EACH trial, a phase Ⅲ study conducted in China, 
Taiwan, Korea and Thailand randomly assigned 371 
patients with advanced disease to receive either combined 
oxaliplatin and fluorouracil/leucovorin (FOLFOX4) or 
doxorubicin[13]. The trial failed to demonstrate a significant 
survival difference between each arm, although a trend 
towards improved outcomes with FOLFOX4 was noted 
(median overall survival was 6.4 mo for FOLFOX4 and 
4.97 mo for doxorubicin; P = 0.7; HR = 0.8; 95%CI: 
0.63-1.02). 
The search for more efficacious treatments eventually 
led to two large randomised phase Ⅲ trials that reported 
a significant survival benefit with sorafenib in close 
succession. The first, conducted in a European, Australian 
and American population, demonstrated a median 
overall survival (OS) of 10.7 mo for patients treated with 
sorafenib (400 mg BD) compared with 7.9 mo for placebo 
(HR = 0.69; 95%CI: 0.55-0.87; P < 0.001)[2]. The latter, 
conducted in the Asian-Pacific region reported that patients 
treated with sorafenib led to a median overall survival of 6.5 
mo compared with 4.2 mo (HR = 0.68; 95%CI: 0.50-0.93; 
P = 0.014)[14]. The survival advantages in both trials were 
modest and neither study established any improvement 
in cancer symptoms or quality of life. Yet this benefit was 
sufficient for sorafenib to become the new standard of care 
for patients with advanced disease. Data extracted from 
the prospectively maintained GIDEON database (Global 
Investigation of Therapeutic Decisions in Hepatocellular 
Carcinoma and of its Treatment with Sorafenib) showed 
that in 3202 patients treated with HCC, adverse events 
were comparable between patients with Child-Pugh A 
and Child-Pugh B cirrhosis[15]. Yet the frequency of serious 
adverse events was higher in the Child-Pugh B group 
(60.4% for Child-Pugh B and 36.0% for Child-Pugh A) 
and median overall survival was shorter 5.2 mo (4.6-6.3) 
for Child-Pugh B and 13.6 mo (12.8-14.7) for Child-Pugh 
A (Table 1). 
Four separate phase Ⅲ trials exploring different multi-
targeted TKIs have now failed to show superior outcomes 
to sorafenib. HCCs are vascular tumours and both VEGF 
and angiopoietin-2 (Ang2) were independent prognostic 
markers during the SHARP trial and have been associated 
with tumour growth and metastatic spread[16]. The success 
of sorafenib was thought to be predominantly related to its 
anti-angiogenic properties and subsequent studies aimed 
to identify more potent anti-angiogenic drugs. Sunitinib, 
a multi-kinase inhibitor targeting VEGFR, PDGFR, c-KIT 
and FLT-3 has been approved for use in gastro-intestinal 
stromal tumours and renal cell carcinomas and was more 
potent that sorafenib in preclinical models[17,18]. Phase Ⅱ 
studies showed modest benefit in HCC at best although 
did highlight potential biomarkers such as interleukin-6, 
stromal-derived factor1alpha and soluble c-KIT, as 
changes in tumour vascular permeability and circulating 
inflammatory molecules were associated with poorer 
outcome[19-21]. Adverse events in these phase Ⅱ studies 
were concerning with liver related toxicities including 
encephalopathy and hepato-renal syndrome and 5%-10% 
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of patients died from treatment related causes. The daily 
dose of 50 mg that is routinely used in other tumour 
types was deemed too high for patients with HCC where 
it precipitated liver toxicities including portal hypertension, 
encephalopathy, oesophageal variceal bleeding, ascites 
and thrombocytopenia. A subsequent head-to-head phase 
Ⅲ study of 1074 patients randomised to either sunitinib or 
sorafenib patients terminated early due to both futility and 
safety concerns[22]. The most frequent grade 3/4 adverse 
events in the sunitinib group were thrombocytopenia 
(29.7%) and neutropenia (25.7%) and in the sorafenib 
group were hand-foot syndrome (21.2%). Overall 
survival was also significantly lower in the sunitinib arm 
(7.9 mo vs 10.2 mo P = 0.0014). Temporary treatment 
discontinuation was more frequent with sunitinib (76.6% 
vs 58.7%). The failure of sunitinib was likely related 
to a combination of inadequate dosing, toxicities and 
trial design, and highlights the need for caution in over-
interpretation of phase Ⅱ data and decision to move to 
Phase Ⅲ trials. 
Pre-clinical studies identified linifanib as a more 
potent dual vascular epidermal growth factor receptor 
(VEGFR) and platelet derived growth factor receptor 
(PDGFR) inhibitor than sorafenib (IC50 = 25 nmol for 
linifanib and IC50 = 57 nmol sorafenib) and VEGFR 
(IC50 = 8 nmol for linifanib and IC50 = 90 nmmol for 
sorafenib)[23]. A single arm phase Ⅱ trial in the first line 
setting resulted in a median overall survival of 9.7 mo 
(10.4 mo in patients with Child-Pugh-A status), which led 
to a non-inferiority phase Ⅲ trial with sorafenib[24]. The 
study of 1035 patients failed to reach its end-point with 
an overall survival of 9.1 mo for linifanib and 9.8 mo for 
sorafenib (HR = 1.04; 95%CI: 0.89-1.22; P = 0.001)[25]. 
Toxicities of hypertension and hepatic toxicities including 
encephalopathy were also higher in the linifanib arm. 
A single arm first line phase Ⅱ study of 55 patients 
treated with brivanib, an ATP competitive inhibitor of 
several kinases including VEGFR2 (IC50 = 25 nmol), 
FGFR-1 (148 nm) and VEGFR1 (380 nmol), resulted 
in a median overall survival of 10.0 mo[26,27]. Phase Ⅱ 
studies confirmed that brivanib was well tolerated and 
one patient had a completed response, three had a 
partial response and twenty-two had stable disease. Yet 
BRISK-FL, the subsequent phase Ⅲ direct comparison 
trial of brivanib and sorafenib, failed to establish a 
significant survival benefit (9.5 mo for brivanib vs 9.9 mo 
for sorafenib; HR = 1.06; P = 0.31)[28]. Due to the trial 
design, in order to demonstrate non-inferiority, brivanib 
needed to produce a hazard ratio between 1 and 1.08, 
which it narrowly failed to reach. The BRISK-FL trial 
highlighted the difficulties in extracting comprehensive 
survival data from non-randomised phase Ⅱ trials. 
Grade 3/4 toxicities for sorafenib and brivanib were 
hyponatraemia (9% and 23% respectively), elevated 
liver enzymes (17% and 14%), fatigue (7% and 15%) 
and hand-foot reaction (15% and 2%). Even if this trial 
had met its end-point of non-inferiority, the significant 
toxicity and economic profiles were not more favourable 
than sorafenib, and thus would have been of little 
meaningful clinical benefit. 
Erlotinib, an epidermal growth factor receptor (EGFR) 
TKI was tested in a first-line phase Ⅲ trial in combination 
with sorafenib compared to placebo/sorafenib in a study of 
720 patients with advanced disease[29]. The combination 
had not previously been tested in phase Ⅱ trials, with 
two single arm phase Ⅱ studies demonstrating modest 
disease control[29-31]. The combined treatment did not 
improve overall survival (9.5 mo compared with 8.5 mo 
for sorafenib alone HR = 0.92; P = 0.2). Toxicities in the 
combination arm were also higher resulting in a reduced 
median treatment duration that may have contributed to 
its diminished efficacy. This trial demonstrates both the 
danger of proceeding to large-scale phase Ⅲ trials without 
a clear signal of efficacy from earlier phase studies and 
the difficulties in combining therapies for HCC (especially 
for drugs that have overlapping toxicities). Robust HCC-
specific phase Ⅰ/Ⅱ studies are needed to identify optimal 
dosing of combination regimens (Table 2). 
FGF has been pursued as a potential target in HCC 
and recent data suggests the FGF signalling pathway may 
play a key role in the development of resistance to anti-
VEGF therapies by activating alternative proangiogenic 
signalling pathways[32]. Forty-six patients who had not 
responded to prior anti-angiogenic therapies were treated 
with brivanib in a single arm phase Ⅱ study[33]. The results 
were promising with a median overall survival of 9.7 mo. 
A subsequent phase Ⅲ trial that was conducted in parallel 
to the BRISK-FL trial compared brivanib with placebo 
Table 1  First line trials with molecular targeted therapies in advanced hepatocellular cancer
Trial Drugs Design n Median survival HR P value Ref.
ASIA-PACIFIC Sorafenib vs placebo Superiority 150   6.5 0.68 0.01 [14]
  76   4.2
SHARP Sorafenib vs placebo Superiority 229 10.7 0.69 0.001 [2]
303   7.9
SUNITINIB Sunitinib vs sorafenib Superiority 530   7.9 1.3 0.001 [22]
544 10.2
BRISK-FL Brivanib vs sorafenib Non-inferiority 577   9.5 1.06 0.31 [28]
578   9.9
LIGHT Linifanib vs sorafenib Non-inferiority 514   9.1 1.04 0.52 [24]
521   9.8
SEARCH Sorafenib/erlotinib vs sorafenib/placebo Superiority 362   9.5 0.92 0.48 [29]
358   8.5
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as second line treatment failed to meet its end point[34]. 
Patients treated with brivanib had a median overall 
survival of 9.7 mo compared with 8.2 mo in the placebo 
arm (P = 0.3). Yet significant improvements were seen in 
the secondary end points of overall response rate (10% 
for brivanib vs 2% for placebo P = 0.003), disease control 
rate (61% vs 40% P ≤ 0.001) and alpha-feto protein 
reduction in 74% of patients with elevated baseline levels 
(> 50% reduction seen in 54% vs 7%). These indicate 
that brivanib has anti-tumour activity despite the negative 
primary outcome. Furthermore, despite stratification the 
placebo cohort had fewer patients with macro-vessel 
invasion and a numerically lower median AFP level. The 
unexpectedly long survival of patients in the placebo 
cohort has been cited as one of the reasons for treatment 
failure. As expected, there were also higher rates of 
treatment discontinuation and elective patient withdrawal 
from the brivanib arm, which may have reduced efficacy 
in this group. 
Mammalian target of rapamycin (mTOR) is upregulated 
in many solid tumours including HCC and appears to have 
a critical role in pathogenesis[35,36]. A second line study 
with the mTOR inhibitor everolimus, offered no survival 
advantage over placebo (7.6 mo for everolimus vs 7.3 
mo; HR = 1.05; P = 0.68)[37]. Ramucirumab is a fully 
human monoclonal antibody against vascular endothelial 
growth factor receptor 2 (VEGFR2), which also failed to 
improve survival compared with placebo (median overall 
survival for ramucirumab was 9.2 mo compared with 7.6 
mo; HR = 0.86, P = 0.13) in the REACH trial[38]. However, 
a pre-planned sub-group analysis revealed that in patients 
with elevated baseline alpha-feto protein (AFP) of more 
than 400 ng/mL, ramucirumab extended both overall and 
progression free survival. Grade 3 toxicities that occurred 
more frequently in the ramucirumab arm included 
hypertension (12% compared with 4%) and fatigue (5% 
compared with 2%), but its toxicity profile is otherwise 
favourable compared to the multi-targeted TKIs. Due to 
this data, a phase Ⅲ trial with second line ramucirumab in 
a select population with AFP > 400 ng/mL is ongoing. 
REASONS FOR THE FAILURE OF PHASE 
Ⅲ TRIALS
Clinical and molecular heterogeneity 
So far all phase Ⅲ trials have unexpectedly failed to 
reach their end-points. There are several reasons for this. 
In the majority of patients with HCC, the cancer arises 
predominantly as a consequence of liver injury secondary 
to a variety of causes. It is clear that underlying liver 
pathology affects both outcome and treatment response, 
suggesting trials need to be stratified according to 
aetiology as well as Child-Pugh status, histological grade 
and stage[39]. Whilst patients with hepatitis B had longer 
overall survival and shorter time to progression following 
treatment with sorafenib in the SHARP trial, these results 
may have been confounded by the imbalance in numbers 
between patients with hepatitis B and C[2]. Without prior 
stratification, it is difficult to analyse the survival between 
sub-groups, highlighting the need for careful trial design. 
Limited understanding of oncogenic drivers mean 
all recent negative phase Ⅲ trials were for “all comers”, 
yet there is marked molecular heterogeneity amongst 
HCC tumours. Extensive genomic studies have revealed 
multiple genetic aberrations with more than 30 somatic 
mutations per tumour[40,41]. The challenge lies in disting-
uishing which are oncogenic drivers and which are bystander 
passenger mutations. Once drivers are identified, trials 
can be tailored to pertinent pathways. However, several 
studies have challenged the idea that single biopsies 
can represent the mutational landscape of the whole 
cancer. With highly mutated tumours such as HCC, the 
key is finding the so-called “trunk” mutations that exist 
in all tumour sites[42]. Even if a driver is found, inhibiting 
pathways may induce resistant mutations. Whilst “liquid” 
biopsies evaluating circulating DNA are under evaluation, 
further research is needed to validate these techniques 
before their use in the clinical setting[43]. One of the 
barriers to drug development is that many previous 
HCC trials did not mandate a tissue diagnosis, relying on 
clinical criteria alone. Several studies have now highlighted 
histological changes following treatment with loco-regional 
therapy such as TACE. In a prospective analysis of 80 
nodules found in explant livers following transplantation 
for HCC, 14 cases of mixed hepatocholangiocellular 
tumours were found in patients who had received TACE 
whilst none were seen in the treatment-naive group, 
implying differentiation into a cholangiocellular phenotype 
for some patients[44]. Furthermore, the lack of histology 
arguably impedes both predictive and prognostic 
biomarker development. For example, a phase Ⅱ trial 
with the selective non ATP competitive c-MET inhibitor 
tivantinib, did not offer a survival advantage in patients 
with advanced HCC but a post study sub-group analysis 
revealed that the overall survival was longer in patients 
Table 2  Second line trials with molecular targeted therapies in advanced hepatocellular cancer
Trial Drugs Design n Median survival HR P value
BRISK-PS Brivanib vs placebo Superiority 263 9.4 0.89 0.33
132 8.2
EVOLVE-1 Everolimus vs placebo Superiority 362 7.6 1.05 0.68
184 7.3
REACH Ramucirumab vs placebo Superiority 277 9.2 0.87 0.14
276 7.6
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with high baseline expression of c-MET (overall survival 
was 7.2 mo for tivantinib and 3.8 mo for placebo HR 
= 0.38, P = 0.01)[45]. A phase Ⅲ trial for patients with 
tumours over-expressing c-MET in the second line setting 
is on going (NCT01755767). Therefore, several agents 
that have failed in phase Ⅲ trials may still be efficacious in 
sub-groups of patients, emphasising the urgent need for 
tissue collection and more sophisticated trial designs that 
accommodate molecular stratification. 
Underlying liver cirrhosis
Another challenge when treating patients with HCC is 
the presence of underlying liver cirrhosis. Historically, 
clinical trials were reserved for patients with good 
hepatic reserve so that competing liver morbidity does 
not overshadow outcomes from malignancy. Yet even 
in patients with preserved baseline hepatic function, 
reaching the optimal maximum tolerated dose in patients 
can be limited by hepatotoxicity. Treatment duration 
in these trials may have been insufficient to elicit a 
response. Liver dysfunction and co-existing cirrhosis 
may affect drug metabolism and due to the consequent 
changes in the pharmacokinetic and pharmacodynamics 
profiles of drugs, there is now a trend to conduct HCC-
specific phase trials rather than extrapolate results from 
“all-comer” phase 1 studies conducted in patients with 
normal or near normal liver function. 
There are no approved therapies in patients who 
progress on sorafenib and who retain well preserved liver 
function and good performance status. Many centres 
use cytotoxic chemotherapy (usually with FOLFOX due 
to results of the EACH trial) despite the lack of clear 
evidence supporting its use. Due to the lack of effective 
second-line therapy, patients are encouraged to enter 
clinical trials of novel agents. By definition, patients 
suitable for second line trials are more likely to have less 
aggressive disease than the wider HCC population in 
whom performance status often deteriorates rapidly on 
progression and is associated with decompensation of liver 
function. In a number of the recent second-line phase 
Ⅲ trials comparing novel therapies to placebo, there 
has been unexpected prolonged survival in the placebo 
cohort, potentially diminishing the survival differences 
between groups. Although the trend for overall survival 
favoured brivanib in the second line BRISK-PS trial, the 
results were non-significant suggesting the study was 
not sufficiently powered to detect benefits with brivanib 
against a placebo controlled population in whom survival 
was unexpectedly long[34]. 
Novel direct-acting antivirals (DAA) that target HCV-
encoded proteins necessary for viral replication, can offer 
patients with hepatitis C sustained virological responses 
(SVR). The increasing use of these novel agents are 
expected to have a future impact on the incidence of 
HCV related HCC. Yet the presence of advanced fibrosis 
will continue to pose a risk for oncogenesis, even in the 
absence of a detectable viral load, and screening high 
risk individuals is still required[46]. The development 
of molecular predictive biomarkers could help identify 
patients that require ongoing surveillance. Furthermore, 
biomarker based stratification could be used to enrich 
HCC chemoprevention trials[47]. 
Response evaluation
Finally, response criteria in trials must be chosen carefully. 
Traditional endpoints such as tumour shrinkage relate 
to chemotherapy treatments and may not be applicable 
when assessing the benefits of targeted treatments, which 
can be cytostatic rather than cytoreductive[48]. Drugs 
that have been deemed failures in phase Ⅲ studies may 
have therapeutic activity in HCC, but insufficient potency 
to improve conventional end-points in phase Ⅲ trials[49]. 
Furthermore liver disease can elicit an inflammatory 
response, which can be mistaken for progression resulting 
in premature cessation of treatment. Thus the use of 
traditional imaging has been highlighted as insufficient in 
assessing response in HCC whereby functional imaging 
provides more useful information. RECIST criteria that 
is routinely used to measure disease response in many 
solid tumours, has been recognised as insensitive in HCC. 
In the SHARP trial, despite an improvement in overall 
survival, only 2% of patients treated with sorafenib 
underwent a response by RECIST criteria. The RECIST 
response criteria were amended to incorporate tumour 
necrosis induced by treatment. The modified RECIST 
(mRECIST) measures arterially enhancing lesions that are 
more representative of residual viable tumour[50,51]. Large 
multi-centre clinical trials in patients with HCC pose unique 
challenges and future study designs must accommodate 
these in order to exploit the true potential of novel agents 
in this disease[52,53]. 
THE GENETIC BACKGROUND OF HCC
In malignancies such as melanoma, key driver mutations 
have now been identified, leading to the use of effective 
targeted therapy that directly translates to improved patient 
survival[54]. Despite the presence of more than 40 somatic 
mutations, there does not appear to be solitary frequent 
genetic defects in the majority of HCC tumours[40,41,55,56]. 
Polyclonality has been noted in patients with HCC reflecting 
a complex genetic landscape. The recently proposed 
concept of “trunk vs branch” heterogeneity can be applied 
to HCC, whereby key mutations that drive tumorigenesis 
exist in both primary and secondary lesions (trunk) and 
need to be distinguished from those that are only present 
in a minority of tissue (branch)[42]. The question remains 
as to whether the vast number of genetic alterations in 
HCC reflect multiple “trunk” mutations that would each 
require inhibition, or if the majority are mere passenger 
alterations that do not need treating. Recent advances 
in high throughput sequencing have uncovered several 
mechanisms of genetic changes, including somatic 
mutations, copy number alterations, HBV integration 
and somatic changes of retrotransposons[55,57]. Whole 
genome sequencing of 88 primary HCC tumours with 
Thillai K et al . Therapy for advanced hepatocellular carcinoma
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matched adjacent liver tissue revealed the predominant 
oncogenic mutation was beta catenin (15.9%) which 
is mutually exclusive with the most frequently mutated 
tumour suppressor gene Tp53 (35.2%) echoing results 
from previous genomic studies[41,55,58,59]. Further mutations 
have been found in ARID1 and 2 (both of which regulate 
chromatin remodelling pathways) and rare mutations in 
RPS6KA3 which codes for RSK2 (a serine threonine kinase 
of the MAPK pathway)[60]. A larger study of 503 HCC liver 
genomes revealed 30 driver genes implicating 11 core 
pathways in tumorigenesis. Recurrent focal amplifications 
were seen in 25% of cases, including telomerase reverse-
transcriptase (TERT) and CCND1-FGF19. Key oncogenic 
pathways included TP53-RB, Wnt and mTOR-PIK3CA[61]. 
Frequently altered in HCC, somatic TERT mutations have 
also been found in pre-cancerous cirrhotic nodules and 
hepatic adenomas, suggesting they play a pivotal role in 
malignant transformation. Sequencing of the promoter 
region of tissue taken from 305 HCCs revealed recurrent 
TERT mutations in 179 samples (59%) at two common 
mutually exclusive hot spots[62]. Yet despite a greater 
understanding of the role of TERT in HCC, its potential as 
a druggable target remains unknown. A small early phase 
Ⅱ study of a telomerase derived peptide, GV1001, failed 
to elicit any responses, although the trial was not enriched 
for TERT mutated tumours[63].
HCC can be classified into two distinct sub-groups 
based on genetic aberrations[64-67]. The proliferative 
subclass is characterised by activation of RAS, mTOR 
and IGF signalling and has been associated with poor 
outcomes. This group can be further divided into those 
with Wnt/transforming growth factor (TGF)-β activation 
and the progenitor cell group that have higher proge-
nitor cell, epithelial cell adhesion molecules and type 
1 cytoskeletal 19 markers. By comparison, the non-
proliferative group is more heterogeneous with less 
shared mutations. The Wnt/beta catenin and JAK/STAT 
signalling pathways are the most frequently affected 
pathways, with alterations in as many as 50%-62.5% 
and 45% of cases respectively[66,68,69]. Several distinct 
protein-altering JAK1 mutations have been identified, 
the majority of which affect the kinase domain[55,70]. HCC 
development is often attributed to chronic inflammation 
triggered by both viral infection and cell necrosis and the 
JAK/STAT pathway has been identified as a promoter of 
carcinogenesis in a sub-set of HCC via cytokine-induced 
JAK/STAT pathway activation[55,71]. 
Copy number analyses using array based comparative 
genomic hybridization (aCGH) have revealed recurrent 
amplifications in genes for p53, Wnt signalling, proliferation 
pathways with recurrent deletions of genes involved in 
the immune response, chromatin remodelling and NF-
kβ pathways[72,73]. Furthermore, the DNA virus hepatitis 
B (HBV), a leading cause of HCC, integrates into the host 
genome affecting gene expression. Deep sequencing 
of HCC samples on a background HBV found direct 
genetic disruption, aberrations of viral promoter-driven 
transcription, viral-human transcription and copy number 
changes confirming theories that alternate aetiologies 
lead to distinct genetic alterations[74,75]. Whole exome 
sequencing of 243 liver tumours revealed mutational 
signatures that appeared to correlate with specific risk 
factors for HCC development including CTNNB1 (alcohol) 
and TP53(HBV)[76]. In addition, different mutations were 
associated with varying clinical outcomes. Early stage 
disease harboured TERT promoter mutations whereas 
FGF, CCDN1, TP53 were associated with more aggressive 
pathology.
Conclusions from these extensive genetic studies have 
highlighted not only the heterogeneity of HCC tumours 
but also the significant differences in key oncogenic drivers 
of HCC compared with many other solid malignancies. In 
breast, colorectal and lung for example, MAPK and PI3K 
as well as EGFR activated pathways dominate progression 
in distinct cohorts[77-79]. However, for HCC Wnt/β-catenin 
and JAK/STAT pathways have consistently been identified 
as responsible for key oncogenic signalling. These 
differences are likely to explain the failures of therapies 
in HCC that have provided benefit in other malignancies. 
Comprehensive genetic mapping will undoubtedly aid 
drug development for HCC but a major challenge is that 
the majority of pathways found remain “undruggable” and 
interacting protein kinases must be targeted instead (Figure 
1). A selection of key pathways and novel agents recently 
or currently under investigation are discussed below. 
EMERGING TARGETS IN DRUG 
DEVELOPMENT 
MEK inhibition
The RAF/MEK/ERK pathway plays a pivotal role in several 
cellular process including proliferation, apoptosis and 
migration[80,81]. Although RAS and RAF mutations are 
uncommon in HCC, there is evidence that this pathway 
is activated in the majority of HCC tumours. Selume-
tinib, a potent selective MEK 1/2 inhibitor, was assessed 
in a single arm phase 2 trial in 19 patients who had 
not received prior systemic therapy. There were no 
responses and time to progression was short (8 wk). 
The trial was subsequently terminated at the interim 
analysis[82]. Examination of pre and post treatment tissue 
revealed that four out of five patients achieved significant 
inhibition of phospho-ERK1/2 in tumours suggesting 
the failure of selumetinib was not due to lack of target 
inhibition. A small study assessing in combination 
with sorafenib resulted in three partial responses and 
six with stable disease. Whilst these numbers were 
small and therefore difficult to interpret, it suggests 
that perhaps this combination should be assessed 
further[83]. A phase Ⅱ study assessing the efficacy and 
safety of combination inhibition using sorafenib and the 
MEK inhibitor refametinib, resulted in a median time 
to progression of 122 d and median OS of 290 d[84]. 
Toxicities however were significant with rash, diarrhoea, 
elevated liver enzymes and vomiting and the majority 
of patients required dose reductions. Interestingly the 
best responders harboured a RAS mutation and a proof 
of concept phase Ⅱ trial using this combination for 
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patients with RAS mutations is on going (NCT01915602). 
Crucially, this study is one of the first attempts to select 
a specific cohort of HCC patients based on molecular 
genotype utilising cfDNA to detect mutations in RAS. 
The study raises a number of important issues regarding 
feasibility and cost given the incidence of RAS mutation 
is approximately 3%-5%, requiring a large cohort of 
patients to be prescreened to identify the small group 
with aberrant genotype (Table 3). 
Anti-angiogenic therapy
HCC is a hyper vascular tumour enriched with high levels 
of angiogenesis due to the presence of growth factors 
such as vascular endothelial growth factor (VEGF) and 
platelet derived growth factor (PDGF)[85]. A meta-analysis 
assessing the prognostic value of VEGF expression 
confirmed that tissue and serum VEGF levels seemed 
to predict poor disease free and overall survival[86]. 
Biomarker data from the SHARP trial also demonstrated 
that VEGF and angiopoietin-2 [(Ang2) a further critical 
molecule in angiogenesis] were independent prognostic 
markers but not predictive of response[16]. Sorafenib 
has anti-angiogenic properties and its success fuelled 
the search for more potent, selective anti-angiogenics. 
Yet several negative clinical trials have questioned 
the emphasis on VEGF inhibition in HCC, supporting 
theories that multiple mechanisms may be in play. As 
discussed the VEGF inhibitors, sunitinib, linifanib and 
brivanib failed to prove non-inferiority compared with 
sorafenib. Some commentators have therefore argued 
that an antiangiogenic monotherapy “ceiling” has been 
reached, and combination strategies will be required 
to extend survival beyond this[87]. Trials of sorafenib 
in combination with other antiangiogenic therapy (beva-
cizumab), chemotherapy (doxorubicin or FOLFOX) or 
other molecularly targeted therapy (e.g., everolimus and 
temsirolimus) are on-going. In order to ensure optimal 
results with these agents, the development of predictive 
biomarkers is needed to select patients who are most 
likely to benefit.
HGF/c-MET pathway
In vitro studies suggest that c-Met may play a role in 
proliferation, angiogenesis and metastatic spread in HCC 
and the hepatocyte growth factor (HGF)-cMET axis is 
therefore an attractive target. Whilst HGF expression in 
HCC tumours is low compared with surrounding liver tissue, 
over-expression of cMET has been observed in nearly 
a quarter of HCC cases and there is some evidence to 
suggest c-MET expression is a poor prognostic marker[88-90]. 
Biomarker data from the SHARP trial revealed that HGF 
levels correlated with tumour size[16]. There is also 
evidence of an interaction between c-MET and both EGFR 
and VEGF[91]. Preliminary data from c-MET inhibition with 
cabozantinib is promising and as previously discussed a 
phase Ⅲ trial with tivantinib in patients with high levels of 
MET expression is on going[92]. 
FGFR inhibition
Fibroblast growth factors are trans membrane receptor 
kinases that signal downstream pathways including 
the RAS-RAF-MAPK. FGF3/4 is expressed in normal 
tissue including benign hepatocytes[93]. Gene array 
studies and Immunohistochemical expression assays 
have shown overexpression of FGF3 and FGF4 in HCC 
tumours that mediate proliferation, cell death and alpha 
Thillai K et al . Therapy for advanced hepatocellular carcinoma
Bevacizumab
EGFR VEGFR PDGFR CMET FGFR
Mapatumumab
Erlotinib
Dovitinib
TGFRB signalling
Cell differentiation
Refametinib
Trametinib
ERK
MEK
RAF
RAS PI3K
AKT
mTOR
CC-223Everolimus
Temsirolimus
Cabozantinib
Tivantinib
INC280
LY2875358
Apatinib
Ramucirumab
Ninetedanib
Tivozanib
Cediranib
Axitinib
Galunisertib
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rapamycin.
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feto protein (AFP) levels[94]. Brivanib, in addition to its 
anti-angiogenic properties as discussed above, is an 
ATP competitive inhibitor of FGF1-3. Although it failed 
to improve survival in the first and second line setting, 
further multi-kinase inhibitors that also target FGFR are 
currently underway. The lack of response to brivanib 
may be partly explained by its use in an unspecified 
population and biomarkers may aid selection of patients 
likely to respond to inhibition. Lenvatinib, an oral multi-
targeted tyrosine kinase inhibitor of VEGFR-1, FGFDR1-4, 
PDGFRβ, RET and KIT is currently under evaluation in a 
non-inferiority study with sorafenib following a phase Ⅱ 
trial which resulted in a median time to progression of 
12.8 mo (95%CI: 7.23-14.7) and median OS of 18.7 mo 
NCT01761266[95]. The REFLECT phase Ⅲ trial comparing 
sorafenib to lenvatinib has recently been completed. This 
trial has attempted to learn the lessons from the previous 
high profile failures described in this article by utilising 
stricter criteria for trial entry, excluding poor prognosis 
groups such as those patients with greater than 50% 
liver involvement, bile duct invasion, or main branch 
portal venous infiltration.
Dovitinib, an FGFR, VEGFR and PDGFR TKI demon-
strated efficacy in xenograft mouse models and is currently 
under investigation in a phase Ⅱ trial[96,97]. FGF19, located 
on chromosome 11q13, a region amplified in 10%-15% 
of HCC tumours, is a potential predictive biomarker for 
FGF inhibitors and FGF19 targeted antibodies are under 
investigation in in vitro models[97]. In vivo studies with 
murine models suggest that dual targeting with FGFR and 
mTOR inhibition impaired tumour growth unlike treatment 
with the FGFR inhibitor alone providing support for 
combination trials[98]. 
TGF-β signalling
TGF-β signalling plays a role in the micro-tumour en-
vironment promoting epithelial-mesenchymal transition 
(EMT), dysplastic nodule formation and subsequent HCC 
development[99-101]. Patients with higher levels of TGF-β 
signalling are associated with larger less differentiated 
tumours with higher levels of AFP[102]. It remains unclear 
whether TGF-β plays a role in a sub-group of patients, 
or in the carcinogenesis of all HCCs due to its dual role in 
tumour suppression in normal tissue and tumour promotion 
in HCC. TGF-β inhibitors modulate EMT leading to reduced 
tumour growth in pre-clinical models. Galunisertib, a 
selective TGF-β TKI is currently under investigation in a 
phase Ⅱ trial (NCT02178358). 
Immunotherapy
Recent years have seen a resurgence in the use of 
immunotherapy, led partly by the success of anti-CTL4 
antibodies in solid tumours such as melanoma and more 
recently antibodies targeting the programmed death (PD) 
receptor and its ligand[103,104]. Immunotherapy works by 
enhancing anti-tumour response, an important mechanism 
in HCC as the surrounding micro-tumour environment 
is rich in immune cells. Tremelimumab, a fully human 
IgG2 monoclonal anti-CTL4 antibody was assessed in a 
phase Ⅱ study of 24 patients with HCC on a background 
of HCV. The drug had a good safety profile and a partial 
response of 17.6% and disease control rate of 76.4%. 
Time to progression was 6.48 m (95%CI: 3.95-9.14). 
Changes were also seen in the predominant variants 
of HCV as well as a reduction in viral loads. These early 
reports are promising and suggest that immunotherapy 
may have the dual benefit of treating both HCC and 
underlying viral hepatitis. Anti-programmed death ligand 
1 (PDL1) inhibitors are checkpoint inhibitors that block T 
cell activation when bound by PD ligands 1 and 2. Patients 
with tumours that over-express PD-L1 are associated with 
a poorer prognosis. In a recently reported phase Ⅰ/Ⅱ dose 
Table 3  Novel agents currently under evaluation in clinical trials
Drug Phase Target Enriched population Trial identifier Study location
Tivantinib Ⅲ MET/tubulin High MET expression NCT01755767 North America, Europe
Axitinib Ⅱ VEGFR/c-KIT/PDGFR No NCT01334112 North America
Tivozanib Ⅰ/Ⅱ VEGFR No NCT01835223 North America
Nintedanib Ⅰ/Ⅱ VEGFR/FGFR/PDGFR No NCT00987935 Asia 
Ramucirumab Ⅲ VEGFR2 AFP > 400 NCT02435433 North America, Asia, Europe
Apatinib Ⅲ VEGFR2 No NCT02329860 Asia
Cabozantinib Ⅲ MET No NCT01908426 North America, Asia, Europe
INC280 Ⅱ MET MET aberration NCT01737827 Asia
LY2875358 Ⅰ/Ⅱ MET/VEGFR No NCT01287546 North America
Refametinib Ⅱ MEK RAS mutations NCT01915602 North America, Asia, Europe
Trametinib Ⅰ/Ⅱ MEK1/2 No NCT02292173 North America
Dovitinib Ⅱ VEGFR, FGFR No NCT01232296 Asia
Temsirolimus Ⅰ, Ⅱ mTOR No NCT01687673 North America
Cc-223 Ⅰ, Ⅱ mTOR No NCT01177397 North America, Europe
Galunisertib Ⅱ TGFRβ No NCT02423343 North America
Mapatumumab Ⅰ/Ⅱ TRAIL-R1 No NCT01258608 North America, Europe
Nivolumab Ⅰ PD1 No NCT01658878 North America, Europe, Asia
Lenvatinib Ⅲ VEGF No NCT01761266 North America, Europe, Asia
Enzalutamide Ⅱ Androgen receptors No NCT02528643 TBC
OMP-54F28 Ⅰ Wnt signalling No NCT02069145 North America
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escalation study, patients received 0.1 to 10.0 mg/kg of the 
anti-PDL1 agent nivolumab intravenously for up to 2 years. 
2 patients had a complete response (CR) and a further 7 
patients had a partial response (PR)[105]. The overall survival 
rate at 6 mo was 72%. Although these results are from a 
very small early phase trial, they are highly encouraging 
and a number of trials using checkpoint inhibitors are now 
planned in both first and second line settings. 
CONCLUSION
The era of personalised medicine and treatment stra-
tification has yet to impact clinical practice of HCC and 
the failure of several clinical trials has been disappointing. 
Nevertheless our understanding of this unique disease 
has improved significantly with the benefit of genomic 
sequencing and biomarker data from clinical trials. Proof 
of concept studies such as the ongoing phase Ⅱ trial with 
refametinib for RAS mutated cancers and tivantinib for 
c-MET positive tumours are a step forward in designing 
adequate trials to maximise potential benefit of novel 
agents in pre-determined sub groups. Molecular testing, 
improved clinical trial design and the development of 
predictive biomarkers should finally see an improvement 
in survival for this global disease. 
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